Massimo Cristofanilli named associate director for precision medicine at Northwestern University Lurie Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

MASSIMO CRISTOFANILLI was appointed associate director for precision medicine and translational research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and director of Northwestern OncoSET.

Cristofanilli will serve as a professor of medicine in the Division of Hematology-Oncology at Northwestern University Feinberg School of Medicine. His work has focused on the translational research and treatment of patients with inflammatory breast cancer.

Cristofanilli comes to Northwestern from Thomas Jefferson University, where he served as director of Jefferson Breast Care Center and deputy director of Translational Research at the Kimmel Cancer Center.

Previously, Cristofanilli was chair of the Department of Medical Oncology at Fox Chase Cancer Center, and executive director of the Morgan Welch Inflammatory Breast Cancer Program and Clinic at MD Anderson Cancer Center.

As associate director for precision medicine and director of Northwestern OncoSET, Cristofanilli will oversee the development of OncoSET and related clinical and research operations. The program involves sequencing tumor genetic profiles and evaluating the results to provide the treatments or clinical trials that will offer the greatest benefit.

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login